{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06008938",
            "orgStudyIdInfo": {
                "id": "CSL222_4001"
            },
            "secondaryIdInfos": [
                {
                    "id": "EUPAS106066",
                    "type": "REGISTRY",
                    "domain": "EU PAS (ENCePP)"
                }
            ],
            "organization": {
                "fullName": "CSL Behring",
                "class": "INDUSTRY"
            },
            "briefTitle": "An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX\u00ae in Patients With Hemophilia B",
            "officialTitle": "An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX\u00ae (Etranacogene Dezaparvovec) in Patients With Hemophilia B",
            "acronym": "IX-TEND 4001",
            "therapeuticArea": [
                "Other"
            ],
            "study": "an-observational-cohort-study-to-characterize-the-effectiveness-and-safety-of-hemgenix-in-patients-with-hemophilia-b"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2043-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2043-08",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-15",
            "studyFirstSubmitQcDate": "2023-08-23",
            "studyFirstPostDateStruct": {
                "date": "2023-08-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "CSL Behring",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false
        },
        "descriptionModule": {
            "briefSummary": "This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX."
        },
        "conditionsModule": {
            "conditions": [
                "Hemophilia B"
            ],
            "keywords": [
                "Hemophilia B",
                "HEMGENIX"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "HEMGENIX",
                    "description": "Patients with hemophilia B treated with HEMGENIX in countries where HEMGENIX is approved for commercial use.",
                    "interventionNames": [
                        "Genetic: HEMGENIX"
                    ]
                },
                {
                    "label": "FIX Prophylaxis",
                    "description": "Patients with hemophilia B on FIX prophylaxis and enrolled in American Thrombosis and Hemostasis Network (ATHN) Transcends (A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders) Hemophilia Cohort, or a similar registry.",
                    "interventionNames": [
                        "Biological: Factor IX (FIX)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "HEMGENIX",
                    "description": "HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.",
                    "armGroupLabels": [
                        "HEMGENIX"
                    ],
                    "otherNames": [
                        "Etranacogene dezaparvovec"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Factor IX (FIX)",
                    "description": "FIX prophylaxis therapy",
                    "armGroupLabels": [
                        "FIX Prophylaxis"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Bleeding Rate (all bleeds) - HEMGENIX Cohort",
                    "description": "Annualised Bleeding Rate (ABR) for all bleeds",
                    "timeFrame": "During the 52 weeks following stable FIX expression (6 to 18 months) in the follow-up period and at Months 6 to: 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 after HEMGENIX treatment."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Bleeding Rate (specified bleed types) - HEMGENIX Cohort",
                    "description": "ABR for spontaneous, FIX-treated, traumatic, and joint bleeds",
                    "timeFrame": "During follow-up period (52 weeks following stable FIX expression [6 to 18 months]), and at Months 6 to: 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 after HEMGENIX treatment."
                },
                {
                    "measure": "Zero bleeds - HEMGENIX Cohort",
                    "description": "Number of patients with zero bleeds",
                    "timeFrame": "During follow-up after HEMGENIX treatment, up to 180 months"
                },
                {
                    "measure": "Correlation analysis - HEMGENIX Cohort",
                    "description": "Correlation analysis of ABR as a function of mean FIX activity.",
                    "timeFrame": "Over the 6 to: 18, 24, 36, 48, 60, 72, 96, 108, 120, 132, 144, 156, 168, and 180 months after HEMGENIX treatment."
                },
                {
                    "measure": "Bleeding Rate - FIX Prophylaxis Cohort",
                    "description": "ABR (total, spontaneous, FIX-treated, traumatic, and joint bleeds)",
                    "timeFrame": "In the period Months 0 to: 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 Months."
                },
                {
                    "measure": "FIX activity - HEMGENIX Cohort",
                    "description": "Mean uncontaminated endogenous FIX activity (%)",
                    "timeFrame": "Day 1, Week 6, and Months 6, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 after HEMGENIX treatment."
                },
                {
                    "measure": "Annualized consumption of FIX replacement therapy - HEMGENIX Cohort",
                    "description": "Mean annualized consumption (IU/kg/Yr) of FIX replacement therapy (including FIX replacement for various clinical scenarios eg, prophylaxis, spontaneous bleeding events, medical procedures, surgery, and trauma).",
                    "timeFrame": "During the follow-up periods (52 weeks following stable FIX expression [6 to 18 months], & at Months 0 to: 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180), & at yearly intervals (ie, at 0 to 1 yr, 1 to 2 yrs, etc, up to 14 to 15 yrs)."
                },
                {
                    "measure": "Annualized consumption of FIX replacement therapy - FIX Prophylaxis Cohort",
                    "description": "Mean annualized consumption (IU/kg/Yr) of FIX replacement therapy (including FIX replacement for various clinical scenarios eg, prophylaxis, spontaneous bleeding events, medical procedures, surgery, and trauma).",
                    "timeFrame": "At Months 0 to: 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180."
                },
                {
                    "measure": "Number of patients remaining free of previous continuous routine prophylaxis - HEMGENIX Cohort",
                    "description": "Number and proportion of patients remaining free of previous continuous routine prophylaxis (FIX replacement therapy)",
                    "timeFrame": "At Months 6 to: 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 after HEMGENIX treatment."
                },
                {
                    "measure": "Target joints occurrence - HEMGENIX Cohort",
                    "description": "The annualized occurrence of target joints (defined as 3 or more spontaneous bleeding events into a single joint within a consecutive 6-month period).",
                    "timeFrame": "After HEMGENIX treatment, during the follow-up periods (52 weeks following stable FIX expression [6 to 18 months], and at Months 6 to: 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180)."
                },
                {
                    "measure": "Target joints resolution - HEMGENIX Cohort",
                    "description": "The percentage of resolution of target joints (target resolution is defined as a recorded target joint with 2 or fewer spontaneous bleeding events within a consecutive 12-month period).",
                    "timeFrame": "During the follow-up period, up to 180 months"
                },
                {
                    "measure": "Target joints - FIX Prophylaxis Cohort",
                    "description": "The annualized occurrence of target joints",
                    "timeFrame": "From Months 0 to 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180."
                },
                {
                    "measure": "Related Serious Adverse Events (SAEs) - number",
                    "description": "Incidence (number) of related SAEs",
                    "timeFrame": "During 15 years of follow-up"
                },
                {
                    "measure": "Related SAEs - percent",
                    "description": "Incidence (percent) of related SAEs",
                    "timeFrame": "During 15 years of follow-up"
                },
                {
                    "measure": "Adverse Events of Special Interest (AESIs) - number",
                    "description": "Incidence (number) of AESIs",
                    "timeFrame": "During 15 years of follow-up"
                },
                {
                    "measure": "AESIs - percent",
                    "description": "Incidence (percent) of AESIs",
                    "timeFrame": "During 15 years of follow-up"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nHEMGENIX Cohort:\n\n* Treatment with commercial HEMGENIX.\n* Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the participating site.\n\nFIX Prophylaxis Cohort:\n\n* Adult patients (\u2265 18 years) with hemophilia B who have consented and enrolled in ATHN Transcends Hemophilia Cohort (or a similar registry) and are receiving FIX prophylaxis therapy.\n\nExclusion Criteria:\n\nHEMGENIX Cohort:\n\n* The patient population that will be observed in this study must not have been treated with etranacogene dezaparvovec in a clinical trial.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with hemophilia B who have been treated with HEMGENIX and are enrolled in either the sponsor's study or the ATHN Transcends study NCT04398628 (Hemophilia Cohort, Gene Therapy Outcomes Arm), and patients who receive routine prophylaxis treatment with FIX replacement therapy that are enrolled in the ATHN Transcends study (Hemophilia Cohort, Natural History Arm), or a similar registry. All patients will provide signed informed consent required for participation.",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Trial Registration Coordinator",
                    "role": "CONTACT",
                    "phone": "1-610-878-4000",
                    "email": "clinicaltrials@cslbehring.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Global Program Director",
                    "affiliation": "CSL Behring",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "American Thrombosis and Hemostasis Network",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "New York",
                    "zip": "14604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Use Central Contact",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.15478,
                        "lon": -77.61556
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.\n\nApplicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.\n\nIf the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP"
            ],
            "timeFrame": "IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.",
            "accessCriteria": "Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.\n\nAn IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.\n\nThe requesting party must execute an appropriate data sharing agreement before IPD will be made available."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006467",
                    "term": "Hemophilia A"
                },
                {
                    "id": "D000002836",
                    "term": "Hemophilia B"
                }
            ],
            "ancestors": [
                {
                    "id": "D000025861",
                    "term": "Blood Coagulation Disorders, Inherited"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000020147",
                    "term": "Coagulation Protein Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6076",
                    "name": "Hemophilia B",
                    "asFound": "Hemophilia B",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9553",
                    "name": "Hemophilia A",
                    "asFound": "Hemophilia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23095",
                    "name": "Blood Coagulation Disorders, Inherited",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21982",
                    "name": "Coagulation Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "T2710",
                    "name": "Hemophilia",
                    "asFound": "Hemophilia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2712",
                    "name": "Hemophilia B",
                    "asFound": "Hemophilia B",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2711",
                    "name": "Hemophilia A",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9576",
                    "name": "Hemostatics",
                    "relevance": "LOW"
                },
                {
                    "id": "M11110",
                    "name": "Liver Extracts",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Coag",
                    "name": "Coagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                }
            ]
        }
    },
    "hasResults": false
}